The ELEGANT trial enrolls all high-risk ER-positive patients, not just those with ESR1 mutations. The rationale is that unlike in metastatic disease, early breast cancer is fundamentally ER-driven. Elicestrin targets both wild-type and mutant ER, making the mutation status less critical for efficacy in this earlier setting.

In neoadjuvant settings, ctDNA monitoring allows for real-time therapy adjustment. Data from the iSpy platform shows 80% of hormone-positive patients clear ctDNA with half the chemotherapy, enabling de-escalation, while the remaining 20% can be identified for escalated treatment.

The landmark DYNAMIC-2 study showed that using ctDNA to guide adjuvant therapy decisions in Stage II colon cancer cut chemotherapy use by 50% (from 30% to 15% of patients). This de-escalation was achieved without any negative impact on patient outcomes, validating the approach.

The practice-changing DYNAMIC trial showed that a ctDNA-guided strategy for stage II colorectal cancer reduces adjuvant chemotherapy use by 50%. Despite this significant de-escalation of treatment, patient outcomes and survival rates were identical to the standard-of-care approach.

A subset of breast cancers (10-15%) are "non-shedders," meaning they don't release detectable ctDNA. Patients with these tumors have excellent outcomes regardless of chemotherapy, suggesting that surgery alone might be a sufficient and less toxic treatment for this specific group.

The next wave of ctDNA research focuses on de-escalation. Trials like SIGNAL ER101 and an Alliance cooperative group study will test withholding intensive adjuvant treatments (like CDK4/6 inhibitors) in high-risk, ctDNA-negative patients, initiating therapy only if they turn positive later. This could spare many from toxicity and cost.

In a subset analysis of the high-risk MONARCH-E trial, an inferred Oncotype score did not identify which patients benefited from the CDK4/6 inhibitor abemaciclib. This indicates that while such scores assess prognostic risk and guide chemotherapy decisions, they are not predictive biomarkers for selecting patients for this targeted therapy.

Modern breast cancer treatment has shifted from a 'one-size-fits-all' aggressive approach to a highly individualized one. By de-escalating care—doing smaller surgeries, minimizing radiation, and sometimes omitting chemotherapy or lymph node biopsies—clinicians can achieve better outcomes with fewer long-term complications for patients with favorable disease characteristics.

Oncotype DX risk scores are more influenced by estrogen-related genes, while other assays like MammaPrint are driven more by genes related to cell proliferation. This fundamental difference in their underlying biology can inform an oncologist's choice of which genomic test is most appropriate for a given patient's tumor.